Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [1]. Core Views - The clinical CRO industry is experiencing a recovery, with increasing demand driven by the global rise in innovative drug financing and the expansion of clinical trial outsourcing. The company is expected to benefit from this trend, with a significant increase in new orders and market share [8]. - The company has established itself as a leader in the clinical CRO market in China, with its market share rising from 8.7% in 2019 to 12.8% in 2023. This growth is attributed to the optimization of supply and the company's strong competitive position [8]. - The company's revenue and profit forecasts indicate a recovery, with expected revenues of 71.29 billion yuan in 2025, 80.19 billion yuan in 2026, and 93.27 billion yuan in 2027, alongside a substantial increase in net profit [8]. Summary by Sections Company Overview - Founded in 2004, the company has grown to become a leading clinical CRO in China, providing comprehensive services for the biopharmaceutical industry through self-built and acquired networks [14]. - The company's ownership structure is stable, with key founders holding significant shares and a management team experienced in top-tier biopharmaceutical companies [15]. Financial Analysis - The company has experienced revenue growth from 254 million yuan in 2012 to 6.603 billion yuan in 2024, with a compound annual growth rate (CAGR) of 28.5%. However, growth has slowed in 2023 and 2024 due to market conditions [19]. - The company’s gross margin has faced pressure, but a recovery is anticipated in 2026 as low-priced orders are cleared and new orders increase [22]. Industry Outlook - The global demand for CRO services is expected to grow, with the penetration rate of outsourced pharmaceutical R&D projected to exceed 50% by 2024 and reach approximately 65% by 2033 [43]. - The number of CRO companies in China has decreased significantly due to market consolidation, enhancing the competitive landscape for leading firms like the company [52]. Business Segments - The company operates primarily in two segments: Clinical Trial Technical Services (CTS) and Clinical Trial Related Services and Laboratory Services. CTS is the cornerstone of the business, covering all phases of clinical trials [54]. - The company has a strong international presence, with operations in 33 countries and a growing number of overseas projects, reflecting its commitment to global expansion [63].

2月3日，泰格医药涨4.97%，成交额10.32亿元。两融数据显示，当日泰格医药获融资买入额5393.21万 元，融资偿还5727.85万元，融资净买入-334.64万元。截至2月3日，泰格医药融资融券余额合计6.31亿 元。 截至9月30日，泰格医药股东户数4.84万，较上期减少6.01%；人均流通股0股，较上期增加0.00%。2025 年1月-9月，泰格医药实现营业收入50.26亿元，同比减少0.82%；归母净利润10.20亿元，同比增长 25.45%。 分红方面，泰格医药A股上市后累计派现24.58亿元。近三年，累计派现11.54亿元。 机构持仓方面，截止2025年9月30日，泰格医药十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股4836.25万股，相比上期增加2509.69万股。中欧医疗健康混合A（003095）位居第四大流 通股东，持股2885.17万股，相比上期增加121.78万股。华宝中证医疗ETF（512170）位居第五大流通股 东，持股1456.80万股，相比上期减少266.25万股。易方达创业板ETF（159915）位居第八大流通股东， 持股1125.86万股，相比上期减少 ...

Core Viewpoint - On January 15, Tiger Med experienced a slight decline of 0.38% with a trading volume of 700 million yuan, indicating a low level of financing and margin trading activity [1][2]. Financing Summary - On January 15, Tiger Med had a financing buy amount of 39.99 million yuan and a financing repayment of 40.44 million yuan, resulting in a net financing outflow of 446,300 yuan. The total financing and margin trading balance reached 675 million yuan [1]. - The current financing balance is 673 million yuan, which accounts for 1.45% of the circulating market value, indicating a low level compared to the past year [1]. Margin Trading Summary - On January 15, Tiger Med repaid 100 shares in margin trading and sold 1,300 shares, with a selling amount of 81,600 yuan based on the closing price. The margin trading balance is 1.59 million yuan, which is also low compared to the past year [1]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [2]. - The main business revenue composition includes clinical trial-related services and laboratory services (52.60%), clinical trial technical services (45.21%), and other services (2.19%) [2]. Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%. However, the net profit attributable to the parent company was 1.020 billion yuan, reflecting a year-on-year increase of 25.45% [2]. Dividend Information - Since its A-share listing, Tiger Med has distributed a total of 2.458 billion yuan in dividends, with 1.154 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Tiger Med had 48,400 shareholders, a decrease of 6.01% from the previous period. The average circulating shares per person remained at 0 shares [2][3]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 48.3625 million shares, an increase of 25.0969 million shares from the previous period [3].

Core Viewpoint - Tiger Med's stock price has shown significant growth in recent months, with a year-to-date increase of 13.28% and a 30.31% rise over the past 20 trading days [1]. Group 1: Stock Performance - As of January 14, Tiger Med's stock price reached 64.23 CNY per share, with a trading volume of 1.49 billion CNY and a market capitalization of 55.304 billion CNY [1]. - The stock experienced a 2.11% increase during the trading session on January 14 [1]. - The stock has seen a 6.52% increase over the last five trading days and an 18.77% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion CNY, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion CNY [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Tiger Med was 48,400, a decrease of 6.01% from the previous period [2]. - The company has distributed a total of 2.458 billion CNY in dividends since its A-share listing, with 1.154 billion CNY distributed over the last three years [3]. - The second-largest shareholder, Hong Kong Central Clearing Limited, increased its holdings by 25.097 million shares to 48.3625 million shares [3].

Group 1 - The core viewpoint of the news is that Tiger Med's stock performance and financing activities indicate a stable yet cautious market position, with a slight increase in stock price and a low financing balance relative to market capitalization [1][2]. Group 2 - On January 8, Tiger Med's stock rose by 0.51%, with a trading volume of 645 million yuan. The net financing purchase was 4.74 million yuan, with a total financing and securities balance of 727 million yuan [1]. - The financing balance of Tiger Med is 724 million yuan, accounting for 1.62% of its circulating market value, which is below the 30th percentile level over the past year, indicating a low financing position [1]. - In terms of securities lending, on January 8, Tiger Med repaid 24,100 shares and sold 300 shares, with a selling amount of 18,200 yuan. The securities lending balance is 2.78 million yuan, which is above the 60th percentile level over the past year, indicating a relatively high position [1]. Group 3 - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, provides professional clinical research services for domestic and international pharmaceutical and health-related products. Its main business revenue composition includes 52.60% from clinical trial-related services and 45.21% from clinical trial technical services [2]. - As of September 30, 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion yuan [2]. - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed in the last three years [3].

Group 1 - The core viewpoint of the news is that Tigermed has experienced fluctuations in its stock price, with a recent increase of 2.03% and a total market capitalization of 44.196 billion yuan [1] - As of September 30, 2025, Tigermed reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.02 billion yuan [2] - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed in the last three years [3] Group 2 - Tigermed operates in the medical and biological sector, specifically in medical research outsourcing, and is involved in various concept sectors including CRO, medical devices, and internet healthcare [2] - The company has seen a decrease in the number of shareholders, with 48,400 shareholders as of September 30, 2025, a reduction of 6.01% from the previous period [2] - The top shareholders include Hong Kong Central Clearing Limited and several ETFs, with notable changes in their holdings compared to the previous period [3]

Core Viewpoint - Tiger Med's stock price has shown a decline of 4.42% year-to-date, with significant drops over various trading periods, indicating potential challenges in the market [1][2]. Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion yuan [2]. - Cumulative cash dividends since the A-share listing amount to 2.458 billion yuan, with 1.154 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 6.01% to 48,400, with an average of 0 shares per shareholder [2]. - The top circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.097 million shares, and other notable funds such as China Europe Medical Health Mixed A and Huabao CSI Medical ETF [3]. Market Activity - On November 26, Tiger Med's stock rose by 2.08% to 51.92 yuan per share, with a trading volume of 154 million yuan and a turnover rate of 0.53% [1]. - The stock has experienced a net inflow of 8.478 million yuan from major funds, with significant buying and selling activity noted [1]. Business Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, specializes in providing professional clinical research services for pharmaceutical and health-related products, covering phases I to IV of clinical trials [1]. - The company's revenue composition includes 52.60% from clinical trial-related services and 45.21% from clinical trial technical services [1]. Industry Classification - Tiger Med is classified under the pharmaceutical and biological sector, specifically in medical services and medical research outsourcing [2]. - The company is associated with various concept sectors, including mid-cap, margin financing, social security heavy positions, medical devices, and internet healthcare [2].

Core Viewpoint - Tiger Med's stock price has experienced a decline of 6.87% year-to-date, with significant drops in recent trading periods, indicating potential challenges in the market despite a recent uptick in share price [1][2]. Group 1: Stock Performance - On November 24, Tiger Med's stock rose by 2.02%, reaching 50.59 CNY per share, with a trading volume of 169 million CNY and a turnover rate of 0.59%, resulting in a total market capitalization of 43.559 billion CNY [1]. - Year-to-date, the stock has decreased by 6.87%, with a drop of 8.98% over the last five trading days, 5.21% over the last 20 days, and 23.83% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion CNY, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion CNY [2]. - The company has distributed a total of 2.458 billion CNY in dividends since its A-share listing, with 1.154 billion CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Tiger Med was 48,400, a decrease of 6.01% from the previous period [2]. - The largest shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.097 million shares to 48.3625 million shares, and other notable shareholders such as China Europe Medical Health Mixed A and Huabao Zhongzheng Medical ETF [3].

Core Viewpoint - Tiger Med's stock price has experienced a decline of 5.53% year-to-date, with a significant drop of 13.21% over the past five trading days, indicating potential concerns among investors regarding the company's performance and market position [1]. Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, reflecting a year-on-year decrease of 0.82%. However, the net profit attributable to shareholders increased by 25.45% to 1.020 billion yuan [2]. - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3]. Stock Market Activity - As of November 20, Tiger Med's stock was trading at 51.32 yuan per share, with a market capitalization of 44.188 billion yuan. The stock has seen a trading volume of 264 million yuan and a turnover rate of 0.90% [1]. - The net outflow of main funds was 22.6355 million yuan, with large orders showing a buy of 466.036 million yuan and a sell of 688.923 million yuan, indicating a higher selling pressure [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Tiger Med was 48,400, a decrease of 6.01% from the previous period. The top circulating shareholder is Hong Kong Central Clearing Limited, holding 48.3625 million shares, an increase of 25.0969 million shares from the previous period [2][3].

Core Viewpoint - Tiger Med's stock price has experienced a decline of 3.17% year-to-date, with a significant drop of 21.49% over the past 60 days, indicating potential challenges in the market [1] Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1] - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1] - The revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1] Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%. However, the net profit attributable to the parent company was 1.020 billion yuan, reflecting a year-on-year increase of 25.45% [2] - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Tiger Med was 48,400, a decrease of 6.01% from the previous period. The average circulating shares per person remained at 0 shares [2] - The top circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.097 million shares, and China Europe Medical Health Mixed A, which increased its holdings by 1.218 million shares [3]